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Background: Colorectal, lung and breast tumors are the most devastating and frequent malignances in clinical oncology. SEREX-analy-
sis of colon cancer leads to identification of more than hundred antigens which are potential tumor markers. With idea that immunoscreen-
ing with pool of allogeneic sera is more productive for antigen isolation, SEREX-analysis was applied to four cases of stages II–IV pri-
mary colon tumor and 22 new antigens were isolated. Objective: To characterize 22 primary colon cancer antigens isolated by SEREX-
technique. Materials and Methods: Allogenic screening, real-time PCR analysis. Results: After allogeneic immunoscreening, for 
5 of 22 (22%) isolated antigens were confirmed colon cancer restricted serological profile solely positive for 14% of tested colon cancer 
sera. Through these five antigens, KY-CC-17/β-actin has cytoskeleton function; KY-CC-14/ACTR1A and KY-CC-19/TSGA2 par-
ticipate in chromosome segregation; KY-CC-12/FKBP4 regulates steroid receptor function and KY-CC-15/PLRG1 is a component 
of spliceosome complex. For the last four antigens tested were found aberrant mRNA expression in some cases of colon tumor. Conclusion: 
The exploration of identified antigens may define suitable targets for immunotherapy or diagnostic of colon cancer.
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Colon cancer as frequent case of colorectal tumors 
along with lung and breast tumors are a significant 
cause of morbidity and mortality in Western popula-
tions associated with a high risk of metastases, recur-
rence, and early patient death. Colon cancer formation 
through adenoma to adenocarcinoma and later to its 
metastatic counterpart involved a multistep cell pro-
cesses those may associated with aberrant expression 
of hundreds of genes [1, 2]. It was a long-standing 
challenge in cancer research if tumor cells proteins 
may specifically recognized as self-antigens (tumor 
associated antigens — TAAs) by patient’s immune 
system. Immunologic methods such as T cell epitope 
cloning [3] and recently emerged as a powerful me-
thod for identification of TAAs serological expression 
cloning (SEREX) [4] applied to different tumors have 
led to the discovery of a subset of antigens recognized 
by CTLs and/or by humoral system in tumor-specific 
manner [5]. TAAs often represent genes with altered 
normal expression, oncogene i.e. overexpressed 
or with activity in tumor cells (activated only in neo-
plastic cells and silence in normal cells, overexpressed 
in tumor cells, mutated genes), those can predict its 
possible association with tumorigenesis [6]. Several 
tumor-specific antigens such as NY-ESO-1, MAGE-1, 
MAGE-3, SSX2, Melan-A, and tyrosinase proteins are 
promising sensitive and specific target molecules for 
cancer screening and diagnosis, cancer immuno-
therapy and development of antigen-specific cancer 
vaccines [7–9].
In recent years a subset of TAAs reacted exclu-
sively or much higher frequently with sera from colon 
cancer patients were uncovered by SEREX-analysis 
of colon primary tumors as well as colon cancer cell 
lines and colon tumor metastasis [10–12]. As it was 
showed, a frequency of TAAs for human primary colon 
tumors is more rare than it was found for its metasta-
ses. It is possible that patients with metastasis may 
have a more augmented IgG response than patients 
with original tumor [11]. Therefore, SEREX-analysis 
of primary colon cancer may define new TAAs useful 
for early tumor diagnosis and immunotherapy inter-
vention. Previously we described of immunogeni city 
of newly identified colon cancer antigens in sera 
of patients of different types of tumors [13]. Here 
we describe identification of these TAAs by SEREX 
methodology in more detail and characterize in terms 
of gene identity, tumor-specific immunogenicity and 
expression in normal colon and colon tumor tissues.
MATERIALS AND METHODS
Tissue samples. The colon primary tumor sam-
ples were obtained from the National Cancer Institute 
(Kyiv, Ukraine) as surgical specimens, frozen in liquid 
nitrogen and stored at −80 °C. The histological clas-
sification of tumors was confirmed by histopathological 
examination at the Department of Pathology, National 
Cancer Institute (Kyiv, Ukraine). Tumor serum samples 
were obtained at the same Institute from 20 patients 
(35–62 years old) including sera samples from 14 co-
lon cancer patients and 6 gastric cancer patients. 
Control sera were obtained from 18 individuals with 
no evidence of malignancy (27–62 years old). All 
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sera samples were processed in the same way and 
stored with 50% glycerol at −20 °C. Consent forms 
were obtained from all patients. The study protocol 
was approved by the Ethics Committee of the Institute 
of Molecular Biology and Genetics.
mRNA preparation and construction of cDNA 
libraries. Normal colon and colon primary tumor 
samples were obtained as surgical specimens and 
frozen in liquid nitrogen with following storage at 
−80 °C. Total RNA was prepared by the guanidinium 
thiocyanate method [14], and mRNA was puri-
fied by the Dynabeads Oligo(dT)25 kit (Dynal, Oslo, 
Norway). 5 ug of mRNA was used for construction 
of oligo(dT)-primed double-stranded cDNA ligated 
into the lambda ZAP II expression vector (Stratagene, 
La Jolla, CA). A total of four cDNA libraries were con-
structed with titers of 1–3•106, and the average inserts 
size of 1.2–1.5 kb (Table 1).
Table 1. Colon cancer cDNA libraries analyzed by SEREX
cDNA 
Library
Colon tumor
(histology; stage) Titer Serum type
Clones 
scree-
ned
Posi-
tive 
clones
Ge-
nes
1C Poorly differentiated, 
metastases in lymph 
nodes; stage IV
2×105 Autologous 2×105 5 2
2C Moderately differen-
tiated, lymph node 
hyperplasia; stage III
2×106 Autologous 2.5×105 3 2
3C Moderately differen-
tiated; stage II
1×105 Autologous 1×105 1 1
4C Moderately differen-
tiated; stage III
0.2×105 Allogene-
ic (pool 
of 6 sera 
from stages 
II–IV colon 
cancer pa-
tients)
0.2×105 37 17
Total 46 22
Immunoscreening. Sera used for immuno-
screening were stored at −20 °C with 50% glycerol. 
In order to remove antibodies reactive with the vector 
system sera prior to immunoscreening were diluted 
at 1:10 in TBS and absorbed through overnight incuba-
tion at 4 °C with Sepharose 4B (Pharmacia, Uppsala, 
Sweden) coupled to lysates from E. coli XL1 and lamb-
da ZAP II-infected E. coli XL1 synthesized as described 
previously [15]. Final sera dilutions (1:100) were pre-
pared in TBS with 0.2% non-fat dried milk (Marwell, 
England) and 0.01% NaN3 as preservative. The cDNA 
libraries were not amplified prior to immunoscreening 
procedure. Immunoscreening of cDNA libraries was 
performed as described [10], except recombinant 
phage plated at concentration of 104/15 cm plate. 
Allogeneic immunoscreening of positive clones 
was developed with sera dilution at 1:100 as de-
scribed [10]. Serum reactivity was detected with the 
alkaline phosphatase substrate, 4-nitro blue tetrazo-
lium chloride/5-bromo-4-chloro-3-indolylphosphate 
(Sigma, St. Louis, MO, USA). Serum was considered 
as reactive when positive staining was observed during 
immunoscreening.
DNA Sequencing. Monoclonalized phage cDNA 
clones were converted to pBluescript phagemids 
by in vivo excision according to user manual (Stratagene, 
La Jolla, CA, USA). The cDNA inserts were sequenced 
with universal M13mp18 primer using the DYEnamic 
ET Terminator Cycle Sequencing Kit ( Amersham Bio-
sciences, Buckinghamshire, England) and ABI Prism 
automated DNA sequencer (Perkin Elmer, Norwalk, CT).
RT-PCR analysis. PCR primers (Invitrogen, 
Paisley, Scotland) with melting temperature between 
60–65 °C were designed to amplify cDNA fragments 
of 400–500 bp represented adjacent exons of cor-
respondent genes in order to check possible genomic 
DNA contamination in PCR product bands. The integrity 
of synthesized cDNAs was determined by the amplifica-
tion of β-actin. RT-PCR was performed using HotStarTag 
DNA polymerase (Qiagen, GmbH, Germany) with 35 cy-
cles of 1 min at 94 °C, 1 min at 65 °C, and 1 min at 72 °C, 
followed by 7 min at 72 °C. The sequences of primers 
used for amplification were as follows: KY-CC-8: forward, 
5´CAGCGTTATTCTCATTGCCTG; reverse, 5´CTCCACT-
GACATCTTCCATTG; KY-CC-12: forward, 5´CAGAAGGTC-
CTGCAGCTCTAC; reverse, 5´GATGGACATATGTTCAT-
GTGC; KY-CC-14: forward, 5´GACAGGCTCCTGAGT-
GAAGTG; reverse, 5´CCTAGGATGGTCAGCAGCAAG; 
KY-CC-15: forward, 5´TTATACGGCATTATCATGGAC; 
reverse, 5´AAGATGCATGGTGCCATTGTC; KY-CC-19: 
forward, 5´ACGGCCGAGCTCATTCACCTG; reverse, 
5´TCTCGGCTCACTTCATCTTAG.
Real-time RT-PCR. For real-time RT-PCR were 
used 6 normal colon cDNAs and 9 colon cancer cDNAs 
with the same primer pairs combination as described 
above. Thermal cycling and fluorescent monitoring 
were performed using an ABI7700 Sequence Analyzer 
(Applied Biosystems, Foster City, CA, USA). As endo-
genous control was used β-actin. Triplicate PCR reac-
tions were prepared for each cDNA sample with SYBR 
Green I PCR mix (Qiagen, GmbH, Germany). PCR 
consisted of 40 cycles of 94 °C denaturation (1 min), 
65 °C annealing (1 min), and 72 °C extension (1 min) 
with following denaturation at 65–94 °C for 20 min 
to determine PCR products melting curve. The point 
at which a PCR product is first detected above a fixed 
threshold (Ct) was determined for each sample, and 
the average of triplicate samples was calculated. 
Respective Ct va lues were normalized (ΔCt) by sub-
tracting the Ct value obtained for β-actin control. For 
6 normal colon cDNA samples normalized ΔCt was 
calculated as the mean value. The relative concentra-
tions of genes-specific mRNAs in colon cancer cDNAs 
compare to normal colon tissue (ΔΔCt) were calcu-
lated by subtracting the normalized mean ΔCt value 
obtained for normal colon cDNAs from those obtained 
with 9 colon tumor samples (ΔΔCt = ΔCt of tumor — 
ΔCt of normal colon), and the relative concentration 
was determined as 2-ΔΔCt.
RESULTS
SEREX defined cDNAs clones. Immunoscre ening 
of the four primary colon cancer cDNA expression li-
braries with autologous or allogeneic serums produced 
a total of 48 serum-positive clones. Sequence analysis 
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of cDNAs from isolated clones revealed 22 different 
genes those have been deposited at LICR SEREX data-
base (http://www.licr.org/SEREX.html) under KY-CC-
1-KY-CC-22 designation. For libraries 1C-3C screened 
with autologous serums were isolated 9 clones those 
represent 5 different genes. For library 4C screened with 
pool of 6 allogeneic sera obtained from colon cancer 
(stages II–IV) patients were isolated 37 clones those 
represent 17 different genes. The largest proportion 
of antigens has been isolated during allogeneic im-
munoscreening of library 4C in contrast to the other 
free libraries screened with autologous serums (see 
Table 1). All of isolated antigens, except KY-CC-20 are 
genes with known function (Table 2). Searching for 
homology to previously SEREX-defined genes at LICR 
SEREX database (http://www.licr.org/SEREX.html) 
revealed that 6 (KY-CC-2, 5, 6, 15, 16, 21) through 
22 antigens isolated at this work have been identi-
fied previously in different tumors and only KY-CC-16, 
21 found for colon cancer. Despite as much as five 
libraries have been analyzed, SEREX-defined clones 
were unique for each immunoscreened library (see 
Table 2). Analysis of antigen’s molecular functions 
showed that at least 8 antigens are involved in the re-
alisation of the genetic information (KY-CC-1/RPL18, 
KY-CC-2/se2–2, KY-CC-5/EEF1A1, KY-CC-8/BRCA2, 
KY-CC-13/RPLP0, KY-CC-15/PLRG1, KY-CC-18/
GNB2L1, KY-CC-22/TRIP11) (see Table 2). The 7 anti-
gens participate in cell proliferation, development and 
apoptosis (KY-CC-7/PDAP1, KY-CC-8/BRCA2, KY-
CC-10/TRIM2, KY-CC-11/BTN3A3, KY-CC-18/GNB2L1, 
KY-CC-19/TSGA2, KY-CC-21/UACA), other 2 (KY-CC-3/
COX1, KY-CC-4/TALDO1) revealed metabolic activity, 
6 antigens (KY-CC-9/CXCR4, KY-CC-11/BTN3A3, KY-
CC-12/FKBP4, KY-CC-16/BRAP, KY-CC-18/GNB2L1, 
KY-CC-22/TRIP11) are involved in cell signalling and 
5 antigens (KY-CC-6/COL1A1, KY-CC-12/FKBP4, KY-
CC-14/ACTR1A, KY-CC-16/BRAP, KY-CC-17/ACTB) 
participate in restructuring of the cytoskeleton and cell 
adhesion (see Table 2). It should be noted that some 
antigens at least KY-CC-8/BRCA2, KY-CC-11/BTN3A3, 
KY-CC-12/FKBP4, KY-CC-18/GNB2L1 and KY-CC-22/
Table 2. Characterization of antigens identified by immunoscreening of colon cancer cDNA expression libraries
Antigen Gene homology Molecular Function
KY-CC-1/RPL18 Ribosomal protein L18 (RPL18) RNA synthesis. Part of the 60S ribosomal subunit
KY-CC-2/se2–2 CEP290 gene, Aliase CTCL tu-
mor antigen se2–2
Part of the tectonic-like complex which is required for tissue-specific ciliogenesis and may regulate 
ciliary membrane composition. Activates ATF4-mediated transcription
KY-CC-3/COX1 Cytochrome c oxidase subunit 
I (COX1)
Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxy-
gen to water
KY-CC-4/TALDO1 Transaldolase 1 (TALDO1) The key enzyme of the pentose phosphate pathway and important for the balance of metabolites 
in the pentose-phosphate pathway
KY-CC-5/EEF1A1 Translation elongation factor 
1 alpha 1 (EEF1A1)
Promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein 
biosynthesis
KY-CC-6/COL1A1 Collagen, type I, alpha 1 
(COL1A1)
The collagen type I, alpha 1, play role in fibril forming, putative downregulated c-Myc target gene
KY-CC-7/PDAP1 PDGFA associated protein 
1 (PDAP1)
Enhances PDGFA-stimulated cell growth in fibroblasts, but inhibits the mitogenic effect of PDGFB
KY-CC-8/BRCA2 BRCA2 region, mRNA se-
quence CG016
Important for cell cycle control and DNA repair through homologous recombination, also involved 
in embryonic cellular proliferation
KY-CC-9/CXCR4 Chemokine (C-X-C motif), re-
ceptor 4 (fusin) (CXCR4)
Receptor for the CХC chemokine. Acts as a receptor for extracellular ubiquitin. Involved in hemato-
poiesis, cardiac ventricular septum formation and mediates LPS-induced inflammatory response
KY-CC-10/TRIM2 Tripartite motif-containing 
2 (TRIM2)
UBE2D1-dependent E3 ubiquitin-protein ligase that mediates the ubiquitination of NEFL and 
of phosphorylated BCL2L11. Plays a neuroprotective function
KY-CC-11/BTN3A3 Butyrophilin, subfamily 3, mem-
ber A3 (BTN3A3)
Plays a role in T-cell responses in the adaptive immune response. Also, the proteins of this family 
play role in cell proliferation and development
KY-CC-12/FKBP4 FK506 binding protein 4 (59kD) 
(FKBP4)
Immunophilin protein with PPIase and co-chaperone activities. Component of steroid receptors 
hete rocomplexes through interaction with heat-shock protein 90 (HSP90). Acts also as a regulator 
of microtubule dynamics
KY-CC-13/RPLP0 Ribosomal protein, large, 
P0 (RPLP0)
Ribosomal protein (60S) is the functional equivalent of E. coli protein L10
KY-CC-14/ACTR1A ARP1 actin-related protein 
1 homolog A, centractin alpha 
(yeast) (ACTR1A)
Component of a multi-subunit complex involved in microtubule based vesicle motility. It is associ-
ated with the centrosome
KY-CC-15/PLRG1 Pleiotropic regulator 
1 (PRL1 homolog) (PLRG1)
Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is re-
quired for activating pre-mRNA splicing
KY-CC-16/BRAP BRCA1 associated protein 
(BRAP)
Negatively regulates MAP kinase activation by limiting the formation of Raf/MEK complexes proba-
bly by inactivation of the KSR1 scaffold protein. May also act as a cytoplasmic retention protein with 
a role in regulating nuclear transport
KY-CC-17/ACTB Actin, beta (ACTB) Actins are highly conserved proteins that are involved in various types of cell motility and are ubiqui-
tously expressed in all eukaryotic cells
KY-CC-18/GNB2L1 Guanine nucleotide binding 
protein (G protein), beta poly-
peptide 2-like 1 (GNB2L1)
Involved in the recruitment, assembly and/or regulation of a variety of signaling molecules and plays 
a role in many cellular processes. It is a part of the 40S ribosomal subunit
KY-CC-19/TSGA2 H. sapience testes specific 
A2 homolog (mouse) (TSGA2)
May play an important role in male meiosis (By similarity). It is necessary for proper building of the 
axonemal central pair and radial spokes
KY-CC-20/IM-
AGE:4893383
EST: IMAGE: 4893383 No data available for molecular function
KY-CC-21/UACA Uveal autoantigen with coiled-
coil domains and ankyrin re-
peats (UACA)
Regulates APAF1 expression and plays an important role in the regulation of stress-induced apop-
tosis. Promotes apoptosis by regulating three pathways, apoptosome up-regulation, LGALS3/galec-
tin-3 down-regulation and NF-kappa-B inactivation
KY-CC-22/TRIP11 TRIP11 H. sapiens thyroid hor-
mone receptor interactor 11
Binds the ligand binding domain of the thyroid receptor (THRB) in the presence of triiodothyronine 
and enhances THRB-modulated transcription. Golgi auto-antigen
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TRIP11exhibit multiple functions and were classified 
in different categories.
Allogeneic immunoscreening of SEREX-de-
fined antigens. In order to determine colon cancer 
related serological profile of identified antigens alloge-
neic immunoscreening have been performed with sera 
obtained from 14 colon cancer and 6 gastric tract cancer 
patients, as well as 18 healthy donors. Eight of 22 tested 
antigens reacted with both normal and cancer sera 
samples; two antigens were positive only for normal sera; 
seven antigens showed no reaction with any sera and 
five antigens solely positive only for colon cancer sera 
(Table 3). For some antigens reacted with cancer and 
normal sera previously showed their association with au-
toimmune, inflammatory-related or non-cancerous (viral) 
diseases (see Table 3). In addition, KY-CC-1/RPL18, 
KY-CC-8/CG016, KY-CC-18/GNB2L1 and KY-CC-22/
FLJ20542 may represent novel tumor-independent 
occurring autoantigens firstly isolated in this work. 
KY-CC-21/UACA, KY-CC-18/GNB2L1 and KY-CC-6/
COL1A1 autoantigens revealed the highest percentage 
reactivity with both normal and cancer serums tested, 
ranging from 29% to 100% (see Table 3). Five antigens 
with colon-cancer specific serological profile, namely 
KY-CC-12/FKBP4, KY-CC-14/ACTR1A, KY-CC-15/
PLRG1, KY-CC-19/TSGA2, KY-CC-17/β-actin were reac-
ting totally for 14% of tested colon cancer sera samples 
(Table 4). Through these antigens only KY-CC-15/
PLRG1 was previously identified by SEREX-analysis 
in hepatocellular carcinoma (data unpublished), for the 
others have not been documented their reactivity with 
any tumor patients sera.    
Table 3. SEREX-defined antigens with not colon cancer related serological 
profile
Antigen
Serum reactivity (number 
of positive sera/number 
of sera analysed)
Association with 
autoimmune 
dise ase2/refe-
rence
Colon 
tumor1
Gastrict 
tract tu-
mor
Healthy 
donors
KY-CC-1/RPL18 1/14 0/6 1/18 No data
KY-CC-2/se2–2 0/14 2/6 1/18 No data
KY-CC-3/COX1 0/14 0/6 0/18 HT [16]
KY-CC-4/TALDO1 0/14 0/6 0/18 MS [17]
KY-CC-5/EEF1A1 2/14 0/6 3/18 No data
KY-CC-6/COL1A1 12/12 NT 11/11 PBC [18], AP [19]
KY-CC-7/PDAP1 0/14 0/6 0/18 No data
KY-CC-8/CG016 1/14 0/6 1/18 No data
KY-CC-9/CXCR4 0/14 0/6 0/18 No data
KY-CC-10/TRIM2 0/14 0/6 0/18 No data
KY-CC-11/BTN3A3 0/14 0/6 0/18 MS [20]
KY-CC-13/RPLP0 0/14 0/6 1/18 SLE [21]
KY-CC-16/BRAP 0/14 0/6 0/18 No data
KY-CC-18/GNB2L1 5/9 NT 9/11 No data
KY-CC-20/IMAGE:4893383 1/7 NT 2/11 No data
KY-CC-21/UACA 5/14 1/6 5/18 Panuveitis [22]
KY-CC-22/FLJ20542 1/14 0/6 2/18 No data
Note: 1Data of serum reactivity not include reactivity with autologous or pool 
of allogeneic sera used for initial SEREX-analysis. 2Abbreviations: PBC — pri-
mary biliary cirrhosis; AP — adult periodontitis; MS — multiple sclerosis; SLE — 
systemic lupus erythematosus; HT — Hashimoto’s thyroiditis.
mRNA expression profile of serologically de-
fined colon cancer specific antigens. KY-CC-12/
FKBP4, KY-CC-14/ACTR1A, KY-CC-15/PLRG1 and 
KY-CC-19/TSGA2 defined by allogeneic immuno-
screening as colon cancer specific antigens were 
tested RT-PCR and real-time RT-PCR for 6 normal 
colon cDNAs and 9 colon cancer cDNAs.
Antigens tested by RT-PCR were positive for all co-
lon cancer cDNAs; KY-CC-15/PLRG1 and KY-CC-19/
TSGA2 were positive for all 6 normal colon cDNAs, 
therefore KY-CC-12/FKBP4 and KY-CC-14/ACTR1A 
were positive only for 4 normal colon cDNAs and very 
weak bands observed for these genes for the other 
2 normal colon cDNAs (data not shown). The rela-
tionship between tested antigens mRNA expression 
levels and serological reactivity was not examined for 
respective colon cancer patients due to their sera were 
not available for typing.
According to the result of real-time RT-PCR, KY-
CC-14/ACTR1A mRNA showed increased expression 
level at 2.5–7.7 times for 8 through 9 tested colon can-
cer cDNAs compare to normal colon (Figure, a). So, KY-
CC-14/ACTR1A may have slightly upregulated mRNA 
expression level as mean at 3.5 times in colon tumors.
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Figure. Real-time RT-PCR results for relative expression level 
of identified colon cancer related antigens in 9 tested colon 
cancer cDNA samples. Expression level of antigens in normal 
colon referred as 1 in all cases
KY-CC-15/PLRG1 and KY-CC-19/TSGA2 showed 
heterogeneous mRNA expression profile in colon tumor 
samples with exceptionally high levels of transcripts com-
pare to normal colon associated with the colon cancer 
case N7 (80 and 88 times elevation, correspondently) 
(Figure, b, c). KY-CC-19/TSGA2 mRNA expression also 
increased at 7 times in tumor case N3 and at 10 times 
in tumor case N9, despite for colon cancer cases 
NN 1, 2, 4, 5, 8 its normal expression down regulated 
at 2–3.5 times (Figure, b). KY-CC-15/PLRG1 mRNA 
in addition to tumor case N7 have slightly increased ex-
pression at 3 times in tumor case N3 and near the same 
level of expression compare to normal colon in tumor 
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cases NN 1, 2, 4, 5, 6, 8, 9 (difference range at 0.48–1.96) 
(Figure, c). KY-CC-15/PLRG1 and KY-CC-19/TSGA2 rep-
resent the genes with selective activation of normal 
expression in some cases of colon cancer and may 
be immunogenic as aberrantly expressed.
By real-time RT-PCR result KY-CC-12/FKBP4 mRNA 
normal expression down regulated at 11–25 times in tu-
mor cases NN 2, 3, 8 and at 3.1 and 3.7 times in tumor 
cases NN 4, 6, respectively (Figure, d). In the others 
four cases of tested tumors, KY-CC-12/FKBP4 mRNA 
expression was near at the same range (difference 
at 0.7–1.2 times) as in normal colon. KY-CC-12/
FKBP4 showed a great down regulation of normal ex-
pression in approximately of ⅓ of colon cancer cases.
DISCUSSION
Utilization of SEREX-analysis led to identification 
of a broad spectrum normal and tumor sera IgG reactive 
proteins currently consisted of over 2000 enters at LICR 
SEREX database (http://www.licr.org/SEREX.html). 
Exploration of these proteins in term of tumor-specific 
immunity discovered a subset of antigens as attrac-
tive targets for cancer diagnosis and immunotherapy.
It have been previously showed that primary colon 
tumors analyzed by SEREX methodology may display 
a small number antigens detected by autologous 
sera [10, 12], despite metastasis counterpart more 
productive for serum reactive clones [10]. Recently, 
application of SEREX-analysis to colon cancer cell 
lines and testis cDNA expression libraries immuno-
screened with colon cancer patients allogeneic sera 
led to identification of about ten new antigens with 
colon tumor restricted serological profile. It is also has 
been found a decline in quantity of serum reactive anti-
gens for colon tumor stages II–III patients sera [11, 13]. 
With idea that serum samples from tumor patients may 
differ by cancer-related IgG response and tumor con-
sists a mix of different cells, not one cell line, we used 
for serological screening of one primary colon tumor 
cDNA expression library pool of 6 allogeneic sera along 
with autologous serum immunoscreening of the ot hers 
three synthesized tumor cDNA libraries [13]. Here 
we describe antigens isolated in more detail.
Of isolated 22 different antigens the largest pro-
portion (17 antigens) were derived from the cDNA 
expression library screened with pool of allogeneic 
sera. In contrast, only 5 antigens were obtained 
from the cDNA expression libraries screened with 
autologous sera (see Table 1). SEREX-defined an-
tigens were unique for each cDNA library analyzed, 
i.e. no similar antigens have been found (see Ta-
ble 2). For 16 of 22 SEREX-defined antigens there 
are no data about their immunogenecity in any 
type of cancer according to SEREX database data 
(http://www.licr.org/SEREX.html). So, it is possible 
that complete list of serum IgG reactive antigens for 
colon cancer should be far from completion and many 
other antigens can be isolated using for immuno-
screening a pool of allogeneic sera those increases 
a chance to recognize a more primary colon tumor 
antigens. Antigens identified were characterized ac-
cording their molecular functions and it was shown 
that the most of them are involved in the implementa-
tion of the genetic information including replication, 
transcription, translation and reparation (see Table 2).
Analysis of frequency of the allogeneic sera antibody 
response of healthy donors and colon cancer as well 
as gastric tract tumors patients to the 22 identified 
antigens showed that 5 (22%) antigens, namely KY-
CC-12/FKBP4, KY-CC-14/ACTR1A, KY-CC-15/PLRG1, 
KY-CC-17/β-actin, KY-CC-19/TSGA2 have colon 
cancer-restricted serological profile. Except KY-CC-15/
PLRG1, previously identified by SEREX in hepatocellular 
carcinoma (data unpublished), the others four antigens 
are firstly isolated at this work and all solely positive for 
14% of tested colon cancer allogeneic sera (Table 4). 
During allogeneic immunoscreening some antigens 
showed no reactivity with any type of sera tested (see 
Table 3). We suggest that using a more extended set 
of normal and cancer serum samples as well as mo-
dernization of conditions for large-scale allogeneic 
immunoscreening should be this problem solving.
Table 4. SEREX-defined antigens with colon cancer related serological profile
Antigen
Serum reactivity (number of positive 
sera/number of sera analysed)  Previously 
isolated 
by  SEREX in2
Colon tumor1 Gastrict 
tract tu-
mor
Healthy 
donorsTotal
Reactive 
serum
KY-CC-12/FKBP4 1/14 9 0/6 0/18 No data
KY-CC-14/ACTR1A 1/14 9 0/6 0/18 No data
KY-CC-15/PLRG1 1/14 8 0/6 0/18 Hepatocellular 
carcinoma
KY-CC-17/β-actin 1/14 8 0/6 0/18 No data
KY-CC-19/TSGA2 1/14 9 0/6 0/18 No data
Note: 1Data of serum reactivity not include reactivity with autologous or pool 
of allogeneic sera used for initial SEREX-analysis. 2Data obtained at LICR 
SEREX database.
We were surprised for housekeeping cytoskeletal 
protein β-actin identified as colon cancer antigen. 
Previously have been reported that some patients 
with type 1 autoimmune hepatitis have anti-actin an-
tibody [23] and β-actin also a candidate autoantigen 
in autoimmune inner ear disease [24]. Therefore, 
recently was showed that the cause for the anti-
actin immune response in medullary breast cancer 
(MCB) relates to the actin exposure on the surface 
of apoptotic MCB cells, allow this intracellular an-
tigen to be exposed to the local humoral immune 
system [25]. We suggest that apoptosis or intensive 
necrosis of colon cancer cells may also provoke of hu-
moral immune response to β-actin. As it was showed 
for the other housekeeping gene — ATP6S1, putative 
accessory unit of the vacuolar H+-ATPase complex, 
despite the broad tissue expression it may stimulate 
humoral responses in a significant proportion of mela-
noma and non-small cell lung carcinoma patients 
treated by vaccination with irradiated autologous 
tumor cells without provoking clinical autoimmunity 
[26]. So, study of β-actin immunogenecity and au-
toimmunity in different tumours patients may define 
it is usefulness for detection of apoptotic positive colon 
cancer variants or cancer treatment.
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As it has been recorded previously, immunogene-
city of SEREX-defined antigens may depend on muta-
tion and/or overexpression of correspondent genes 
in tumor cells those also can be contributed to tumor 
formation [6, 27]. Sequenced cDNAs for colon cancer-
specific serum reactive clones have no any muta-
tions according to comparison with relative matches 
in GenBank data. Real-time RT-PCR for KY-CC-12/
FKBP4, KY-CC-14/ACTR1A, KY-CC-15/PLRG1, KY-
CC-19/TSGA2 revealed aberrant distribution its mRNA 
normal level in some tested colon cancer tissues that 
can made them implications in tumor etiologic and 
immunogenecity context.
KY-CC-12/FKBP4 (FKBP52) belongs to a distinct 
group of structurally related immunophilins and par-
ticipates in association with Hsp90 to form chaperoned 
mammalian steroid receptor complexes into a confor-
mation that is optimal for binding hormone [28–30]. 
FKBP4 is expressed at varying levels in all human tis-
sues as well as cultured cells tested and its expression 
is reduced in fibroblastic CCL39 mutant-transformed 
cells or cells able to grow in low serum-containing me-
dium, suggesting that FKBP4 might participate in the 
negative feedback control to cell proliferation [31]. 
Also we found the reduction of FKBP4 mRNA expres-
sion in colon tumor comparing to normal colon tissue 
(Figure, d). Due to one molecule of FKBP4 have stoi-
chiometry in steroid receptor heterocomplexes with 
two molecules of hsp90 determined for glucocorticoid 
receptor [30, 32], progesterone receptor [33], and 
estrogen receptor [34] misbalance in this ratio due 
to decreasing in FKBP4 expression possible for colon 
cancer as well as increasing in heat shock proteins ex-
pression reported for gastrointestinal tumors [35] may 
lead to appearance of nonfunctional steroid receptor. 
In case of ER-β those can mediated protective effects 
of estrogen replacement therapy and its protein ex-
pression is markedly and specifically reduced in colon 
cancers compared to adjacent normal colon in vivo [36], 
process described above may be alternative way to in-
activation of ER-β in ER-β positive colon cancer cells 
as more early event in molecular etiologic of this tumor. 
Down regulation of FKBP4 expression in colon cancer 
cells can disrupt normal protein processing for which 
multiple isoforms have been found [28], as well as con-
centration in cell to form complex with hsp90 with fol-
lowing generation of aberrant set of peptides presenting 
by MHC. Recently the same mechanism was proposed 
for down-regulated genes found by SEREX-analysis 
as immunogeneic antigens [11].
KY-CC-14/ACTR1A (actin-related protein 1 ho-
molog A, centractin alpha (yeast)) is an actin-related 
protein, and is approximately 60% identical at the amino 
acid level to conventional actin. It comprises the most 
abundant 42.6 kD subunit in the dynactin complex 
involved in a diverse array of cellular functions, inclu-
ding ER-to-Golgi transport, the centripetal movement 
of lysosomes and endosomes, spindle formation, chro-
mosome movement, nuclear positioning, and axono-
genesis [37]. We found for approximately half of tested 
colon tumors increasing of ACTR1A mRNA expression 
at 3–8 times compare to normal tissue (Figure, c), those 
can predict immunogenecity of correspondent protein. 
Recently have been found that dynactin complex may 
participate in maintaining of multicentric chromosomes 
during chromosome segregation in tumor cells [38]. So, 
ACTR1A may associated as one of many components 
for survival of cancer cells with multiple chromosome 
aberration. The next study of dynactin complex in tu-
mor cells may define appropriated targets for therapy 
oriented on disruption of control mechanism aberrant 
chromosome segregation.
KY-CC-19/TSGA2 represents protein, also known 
as RSPH1, is present in the sperm flagellum [39]. This 
protein is a homolog for mouse testes specific A2 pro-
tein and has unknown function in the humans [40]. 
Mouse TsgA2, initially believed to be confined to the 
testis in male mice [41, 42]. TsgA2 have been iso-
lated using testis-specific polyclonal antibodies from 
an expression cDNA library prepared from the mouse 
testis [41]. Immunohistochemical examination revealed 
TsgA2 specific association with the metaphase chro-
mosomes and spindles suggesting that the protein 
plays important roles in male meiosis [41]. We found 
that KY-CC-19/TSGA2 mRNA expression in human not 
restricted only to reproductive tissues because it was 
found in testis, normal colon and colon tumors. In two 
through 9 colon tumors tested TSGA2 mRNA expression 
was elevated at about 10 times and for the other one 
at near 90 times compare to normal colon (Figure, a). 
Such overexpression of TSGA2 in some cases of colon 
tumors may be a reason for its immunogenecity. Ac-
cording to postulated for TsgA2 important role in meta-
phase chromosomes segregation it is also possible, 
as in case of ACTR1A, that multiple chromosome aber-
ration in tumor cells require some specific modification 
in molecular machinery acted in cell division and human 
TSGA2 one of that for tumorgenesis process.
KY-CC-15/PLRG1 represents human homolog 
to pleiotropic regulator 1 found in Arabidopsis [43]. 
The human proteins CDC5L (hCDC5) and PLRG1 are 
both highly conserved components of a multiprotein 
complex that is a subunit of the spliceosome and 
interaction between them is essential for pre-mRNA 
splicing progression [44, 45]. It has been shown that 
overexpression of CDC5L in mammalian cells shorte-
ned the G2 phase of the cell cycle and a dominant 
negative mutant of the protein lacking the activation 
domain slowed G2 progression and delayed entry 
into mitosis [46] and also PLRG1 deficiency causes 
an earlier cell cycle arrest, as cells cannot progress 
through S phase [45]. We found that in one case of co-
lon tumor mRNA expression of KY-CC-15/PLRG1 was 
elevated at 80 times compare to normal colon those 
can be as reason for IgG antibody response in case 
of tumors with shortened G2 phase, i.e. with rapidly 
growth characteristic.
In conclusion, we found that using pool of al-
logeneic sera obtained from colon cancer patients 
for SEREX-analysis of colon primary cancer may 
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be an optimal way to overcome a difficulty with isola-
tion of low number immunoreactive antigens for this 
tumor. We suggest that best way to complete SEREX 
characterization of all possible colon cancer antigens 
is using different stage colon tumors for serum im-
munoscreening each with pools of sera obtained also 
for different stage tumors. It was found that primary 
colon tumors have new unique antigens in comparison 
to previously isolated, because majority of the last have 
been obtained for colon cancer cell lines. We con-
firmed for five through 22 antigens isolated at this work 
its colon-cancer restricted serological profile requests 
its next exploration to define suitable targets for colon 
tumor therapy or diagnostic.
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